GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » Beneish M-Score

ENGN (enGene Holdings) Beneish M-Score : 0.00 (As of Dec. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for enGene Holdings's Beneish M-Score or its related term are showing as below:

During the past 4 years, the highest Beneish M-Score of enGene Holdings was 0.00. The lowest was 0.00. And the median was 0.00.


enGene Holdings Beneish M-Score Historical Data

The historical data trend for enGene Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enGene Holdings Beneish M-Score Chart

enGene Holdings Annual Data
Trend Oct20 Oct21 Oct22 Oct23
Beneish M-Score
- - - -

enGene Holdings Quarterly Data
Oct20 Oct21 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of enGene Holdings's Beneish M-Score

For the Biotechnology subindustry, enGene Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


enGene Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, enGene Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where enGene Holdings's Beneish M-Score falls into.



enGene Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of enGene Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jul24) TTM:Last Year (Jul23) TTM:
Total Receivables was $0.24 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $262.69 Mil.
Total Assets was $266.88 Mil.
Property, Plant and Equipment(Net PPE) was $2.80 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.29 Mil.
Selling, General, & Admin. Expense(SGA) was $18.84 Mil.
Total Current Liabilities was $13.46 Mil.
Long-Term Debt & Capital Lease Obligation was $23.09 Mil.
Net Income was -14.148 + -14.984 + -10.711 + -82.497 = $-122.34 Mil.
Non Operating Income was -0.047 + 0.091 + -0.43 + -71.286 = $-71.67 Mil.
Cash Flow from Operations was -7.181 + -14.162 + -7.37 + -6.776 = $-35.49 Mil.
Total Receivables was $2.55 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $41.84 Mil.
Total Assets was $46.28 Mil.
Property, Plant and Equipment(Net PPE) was $0.44 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.13 Mil.
Selling, General, & Admin. Expense(SGA) was $5.19 Mil.
Total Current Liabilities was $9.10 Mil.
Long-Term Debt & Capital Lease Obligation was $68.68 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.241 / 0) / (2.548 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (262.694 + 2.804) / 266.879) / (1 - (41.839 + 0.441) / 46.282)
=0.005175 / 0.08647
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.126 / (0.126 + 0.441)) / (0.289 / (0.289 + 2.804))
=0.222222 / 0.093437
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.837 / 0) / (5.186 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((23.092 + 13.458) / 266.879) / ((68.68 + 9.103) / 46.282)
=0.136953 / 1.680632
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-122.34 - -71.672 - -35.489) / 266.879
=-0.056876

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


enGene Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of enGene Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


enGene Holdings Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Executives
Forbion Growth Opportunities Fund I Cooperatief U.a. 10 percent owner GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Fonds De Solidarite Des Travailleurs Du Quebec 10 percent owner 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Richard M Glickman director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson director, officer: Chief Executive Officer 8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Gerald A Brunk director C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos director BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan officer: Int. Chief Financial Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung officer: Chief Technology Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols officer: Pres. & Chief Operating Ofc. 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan officer: Chief Scientific Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v. 10 percent owner GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Management B.v. 10 percent owner C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807